Core Insights - The equity market has shown positive trends this year, leading to most equity funds achieving positive returns [1] - However, some funds, particularly Minsheng Jianyin Fund's Minsheng Jianyin Preferred Stock, have performed poorly, ranking at the bottom among peers [1] Fund Performance Summary - As of October 20, the net value of Minsheng Jianyin Preferred Stock has decreased by 6.53%, making it the worst-performing active equity fund under Minsheng Jianyin [1] - Other funds under Minsheng Jianyin, such as Minsheng Jianyin Pension Service Mixed Fund and Minsheng Jianyin Financial Preferred Mixed A, also reported negative returns [1] - A total of 10 active equity funds from Minsheng Jianyin have underperformed against their benchmarks this year, with at least three funds, including Minsheng Jianyin Preferred Stock, lagging by over 10 percentage points [1] Long-term Performance Analysis - The two-year, three-year, and five-year returns for Minsheng Jianyin Preferred Stock are -10.22%, -28.46%, and -36.04%, respectively, underperforming their benchmarks by 34.18, 49.15, and 32.73 percentage points [1]

Core Insights - In the first three quarters of this year, 98% of the 976 comparable ordinary equity funds achieved positive performance, with only 23 funds experiencing declines [1] Group 1: Top Performing Funds - The top four performing ordinary equity funds, namely Huaan Pharmaceutical Biotechnology Stock A, Huaan Pharmaceutical Biotechnology Stock C, E Fund Information Industry Select Stock A, and E Fund Information Industry Select Stock C, all saw their performance double, with increases of 103.31%, 102.65%, 102.03%, and 101.26% respectively [1] - Huaan Pharmaceutical Biotechnology Stock's second-quarter report indicates heavy investments in companies such as Innovent Biologics, CSPC Pharmaceutical Group, and others, with significant stock price increases, particularly for 3SBio, which surged over four times [1] - E Fund Information Industry Select Stock's top ten holdings are primarily in the semiconductor sector, including companies like NewEase, Huitian Technology, and Tencent Holdings [1] Group 2: Fund Management and Performance - The E Fund Information Industry Select Stock is managed by Zheng Xi, who has extensive experience in equity investment management and has held various roles within E Fund [2] - Other notable funds such as E Fund Strategic Emerging Industries Stock A and C, and Jiashi Mutual Selection Stock A and C, also reported over 90% increases in the first three quarters [2] - Jiashi Mutual Selection Stock focuses on pharmaceutical stocks, with major holdings in companies like Innovent Biologics and Hengrui Medicine, managed by Hao Miao, who has a strong background in biomedical research [2] Group 3: Underperforming Funds - The fund with the largest decline, Minsheng Jianyin Preferred Stock, fell by 7.39%, primarily investing in blue-chip consumer stocks [4] - The fund's top ten holdings include companies like CATL and BYD, with the current manager, Liu Hao, having less than a year of experience [4] - Other underperforming funds include Changxin Consumer Select Quantitative Stock and Qianhai Kaiyuan Traditional Chinese Medicine Stock, both down by over 5% [4]

Group 1 - The core point of the article highlights that the Minsheng Jia Yin Preferred Stock Fund has performed poorly, ranking last with a -9.51% return in the first eight months of the year [1] - As of August 29, the fund's cumulative return since its inception in December 2014 is 53.71%, with a unit net value of 1.7096 yuan [1][2] - The fund has experienced a significant decline of 36.60% over the past three years, indicating a challenging performance period [1][2] Group 2 - The fund's top ten holdings include notable companies such as CATL, BYD, and Hikvision, reflecting a focus on key players in the technology and consumer sectors [1] - The fund manager, Liu Hao, has been managing the public fund since July 2023, previously working as an industry researcher at China International Capital Corporation from July 2018 to July 2020 [1] - Recent performance metrics show a monthly return of 3.52% and a one-year return of 7.05%, but the three-month and six-month returns are -2.65% and -11.70%, respectively [2]

Core Viewpoint - The Minsheng Jianyin Preferred Stock Fund has underperformed significantly, ranking last among equity funds with a -9.51% return in the first eight months of the year [1] Group 1: Fund Performance - As of August 29, the Minsheng Jianyin Preferred Stock Fund has a cumulative return of 53.71% since its inception on December 19, 2014, with a unit net value of 1.7096 yuan [1] - The fund has experienced a substantial decline of 36.60% over the past three years [1] - Recent performance metrics include a -11.70% return over the last six months and a -2.65% return over the last three months [2] Group 2: Fund Management - The fund manager, Liu Hao, has been managing the public fund since July 2023, previously working as an industry researcher at China International Capital Corporation from July 2018 to July 2020 [1] - The fund's top ten holdings include companies such as CATL, BYD, and Hikvision, indicating a focus on technology and consumer sectors [1]

Core Insights - The majority of ordinary stock funds in China have performed well in the first seven months of the year, with 92% of the 983 funds showing positive returns [1] - The top-performing fund, Huaan Medical Biotechnology, achieved a remarkable increase of over 105% [1] - The strong performance of these funds is largely attributed to their heavy investments in the pharmaceutical sector, with several stocks experiencing significant gains [2][3] Fund Performance - Huaan Medical Biotechnology Fund A and C led the performance with increases of 105.40% and 104.88% respectively, heavily investing in companies like Innovent Biologics and Stone Pharma [1] - Other notable funds include Jiashi Mutual Selection and Fortune Medical Innovation, which saw increases of 97.28% and 96.67% respectively, also focusing on pharmaceutical stocks [2] - Funds with over 80% growth include Ping An Medical Selected Stocks and Penghua Medical Technology Stocks, indicating a strong trend in the healthcare investment space [3] Underperforming Funds - Only seven funds experienced declines exceeding 10%, primarily in sectors like consumer goods, new energy, and technology [4] - The Minsheng Plus Silver Preferred Stock Fund saw a decline of 13.06%, with major holdings in companies like CATL and BYD [4] - Other funds with significant declines include Changxin Consumer Selected Quantitative Stocks and Beixin Ruifeng Preferred Growth, both heavily invested in the liquor sector [5]

Core Viewpoint - Minsheng Jia Yin Fund has undergone significant personnel changes, with Zhu Yongming promoted to Deputy General Manager and Ding Hui taking over as Secretary of the Board, both having backgrounds in the major shareholder Minsheng Bank, indicating a continuation of the "Minsheng system" in management [2][5]. Management Changes - Zhu Yongming has effectively taken charge of the investment decision-making committees for equity, fixed income, and asset allocation, becoming the head of investment research despite lacking substantial frontline investment experience [2][4]. - The promotion of Zhu Yongming is seen as a confirmation of his leadership role in investment research, as he had already held key positions in investment decision-making committees prior to his promotion [4][6]. Talent Drain - The fund has experienced a continuous outflow of core investment research talent, starting with the departure of former General Manager Li Caogang, followed by other key personnel, which has negatively impacted fund performance [6][7]. - As of June 9, 2025, several actively managed equity products under Minsheng Jia Yin Fund reported negative returns, highlighting the challenges faced by the investment team [6][7]. Governance Structure Issues - The shareholder structure of Minsheng Jia Yin Fund includes major players like Minsheng Bank and the Royal Bank of Canada, yet this has not translated into sustained growth or stable performance [7][9]. - The fund's management scale has remained below 160 billion since 2022, with significant reductions in the scale of equity and mixed funds, indicating potential governance and operational challenges [7][9]. Market Position and Challenges - Despite a strong background and talent pool, the fund struggles with converting its resources into effective market performance, with a notable concentration of management talent from a single shareholder, which may lead to decision-making biases [9].

Core Insights - Minsheng Jia Yin Fund has reported that 11 of its actively managed equity funds have negative returns this year, with three funds managed by Cai Xiao performing particularly poorly [1][2] Fund Performance Summary - The Minsheng Jia Yin Pension Service Mixed Fund has a return of -40.98% over 3 years and 172 days [1] - The Minsheng Jia Yin Balanced Optimal Mixed A2 Fund has a return of -16.89% over 2 years and 17 days [1] - The Minsheng Jia Yin Preferred Stock Fund has a return of -9.54% over 2 years and 145 days [1] - Liu Xiaohan's Minsheng Jia Yin Quality Consumption Stock A has a return of -43.65% over nearly 4 years, compared to the average return of -17.51% for similar funds [1] - Rui Dingkun's Minsheng Jia Yin Brand Blue Chip Mixed A has a return of -37.08% over approximately 3.5 years [1] Cai Xiao's Fund Management Overview - Cai Xiao has managed three funds with negative returns, including the Minsheng Jia Yin Pension Service Mixed Fund, which has a return of -41.31% since taking over on December 1, 2021 [1][2] - The Minsheng Jia Yin Preferred Stock Fund has seen a decline of 20.06% since Cai Xiao took over on December 28, 2022 [1][2] - The Minsheng Jia Yin Balanced Optimal Mixed A/C has returns of -16.55% and -17.24% since management began on May 5, 2023 [1][2] Fund Details - The Minsheng Jia Yin Balanced Optimal Mixed A/C was established on May 5, 2023, and has seen a net value drop to approximately 0.83 yuan by the end of the year [2] - The top ten holdings of the Minsheng Jia Yin Balanced Optimal Mixed A/C include companies like Hisense Visual, Haier Smart Home, BYD, and CATL [2] Management Background - Cai Xiao has over 9 years of experience managing public funds and has held various roles in investment analysis and management since 2004 [3]

Group 1 - In April, among 1016 comparable ordinary stock funds, 171 funds saw an increase in performance, 3 remained flat, and 842 experienced a decline [1][2] - The pharmaceutical and biopharmaceutical sectors emerged as the leading sectors, significantly boosting the performance of related thematic funds [1][2] - Notable funds with over 10% growth in April include Bank of China Health Stock A (12.65%), Bank of China Health Stock C (12.61%), and Penghua Pharmaceutical Technology Stock A (11.65%) [1][2] Group 2 - Bank of China Health Stock A and C's top ten holdings include major companies such as Heng Rui Medicine, Xin Nuo Wei, and Bai Li Tian Heng [1] - Penghua Pharmaceutical Technology Stock A and C, managed by veteran Jin Xiaofei, reported increases of 11.65% and 11.62% respectively, with significant holdings in companies like Nuo Cheng Jian Hua and Bai Ji Shen Zhou [2] - Hua An Pharmaceutical Biotechnology Stock A and C also performed well, with monthly growth rates of 10.91% and 10.88% [2] Group 3 - On the downside, nine ordinary stock funds fell over 10% in April, primarily in the consumer electronics and new energy sectors [3][4] - Minsheng Jia Yin Preferred Stock Fund recorded the largest decline at -13.71%, with major holdings including Haier Smart Home and BYD [3] - Other funds like Dongwu Double Triangle Stock A and C also faced significant declines of 11.09% and 11.14% respectively, largely due to their investments in new energy and internet platforms [4] Group 4 - HSBC Jin Trust Low Carbon Pioneer Stock A and C experienced declines of 10.07% and 10.11%, with all top holdings in new energy stocks [4] - The cumulative return of HSBC Jin Trust Low Carbon Pioneer Stock C since its inception is a loss of 58.24% as of April 30 [4] - The management of these funds includes experienced professionals with extensive backgrounds in research and investment [3][4]